Navigation Links
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Date:10/11/2011

12, that Omeros will initiate a second Phase 3 trial of OMS302 following discussions with regulators, that OMS302 could represent a significant advance for significant advance for both ophthalmologic surgeons and their patients, and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. (OTCQB: ... that merged with MabVax Therapeutics, Inc. on July ... progress related to the development of its lead ... recovered using the Company,s internally developed antibody discovery ... for multiple antibody based therapeutic and diagnostic products ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... report is available in its catalogue: , , , ... , , http://www.reportlinker.com/p0191978/China-Patient-Monitoring-Market-Outlook-to-2016.html ... China Patient Monitoring Market Outlook to 2016 , , , ... , , "China Patient Monitoring Market Outlook ...
... June 1 Clinicians at Institut Catala d,Oncologia (ICO) in ... using RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate ... the country to receive the fast and efficient treatment. , ... "The treatment went very well and the ...
Cached Medicine Technology:Reportlinker Adds China Patient Monitoring Market Outlook to 2016 2Reportlinker Adds China Patient Monitoring Market Outlook to 2016 3Reportlinker Adds China Patient Monitoring Market Outlook to 2016 4Reportlinker Adds China Patient Monitoring Market Outlook to 2016 5Reportlinker Adds China Patient Monitoring Market Outlook to 2016 6Reportlinker Adds China Patient Monitoring Market Outlook to 2016 7Reportlinker Adds China Patient Monitoring Market Outlook to 2016 8Reportlinker Adds China Patient Monitoring Market Outlook to 2016 9Reportlinker Adds China Patient Monitoring Market Outlook to 2016 10Reportlinker Adds China Patient Monitoring Market Outlook to 2016 11Reportlinker Adds China Patient Monitoring Market Outlook to 2016 12Reportlinker Adds China Patient Monitoring Market Outlook to 2016 13Reportlinker Adds China Patient Monitoring Market Outlook to 2016 14Reportlinker Adds China Patient Monitoring Market Outlook to 2016 15Reportlinker Adds China Patient Monitoring Market Outlook to 2016 16Reportlinker Adds China Patient Monitoring Market Outlook to 2016 17Reportlinker Adds China Patient Monitoring Market Outlook to 2016 18Reportlinker Adds China Patient Monitoring Market Outlook to 2016 19Reportlinker Adds China Patient Monitoring Market Outlook to 2016 20Reportlinker Adds China Patient Monitoring Market Outlook to 2016 21Reportlinker Adds China Patient Monitoring Market Outlook to 2016 22Reportlinker Adds China Patient Monitoring Market Outlook to 2016 23Reportlinker Adds China Patient Monitoring Market Outlook to 2016 24Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4
(Date:8/28/2014)... (PRWEB) August 28, 2014 Millennium Treatment Group ... America is extremely large, and Millennium Treatment Group is working ... treatment that they need. , According to the National ... than 21 million Americans could have benefited from treatment for ... people received help. This means that there is a large ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... plans its exit strategy from the war, now may be ... health care to veterans, says a Perspective piece in the ... go on doing more of the same is to fail ... and population structure pose in the longer run," said William ... Practice, and David Auerbach, from the RAND Corporation, in the ...
(Date:8/28/2014)... Greenwich, CT and Ann Arbor, MI (PRWEB) August 28, ... I portfolio company and the nation’s leading intraoperative neurophysiology ... Gecsey, President and CFO, to the position of Chief ... 2010 as CFO, was promoted to President and CFO ... Biotronic’s continued growth and success. , “Bill’s efforts ...
(Date:8/28/2014)... August 28, 2014 Kirklyn Smith, an office ... may be a new world’s record by walking 5,000 miles ... we are constantly amazed by the thousands of individual stories ... just seem to stand out more than the others. , ... hour step count which tallies a range of 54,823 steps ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2
... in which health care providers are rewarded with more ... in the UK and Australia. The approach has ... Medicare and Medicaid Services (CMS), which is responsible for ... the US is slated for 2013, when hospitals will ...
... strategy for women who can potentially benefit from repeat mammography ... single intervention that is best, according to a study published ... Cancer Institute. Regular mammography screening has been ... ages of 50 and 74 by approximately 23%. However, until ...
... from the Action to Control Cardiovascular Risk in Diabetes ... kind to determine whether intensive blood glucose (sugar) control ... results show that the benefits of intensive therapy need ... cardiovascular disease-related death, increased weight gain, and high risk ...
... ... winning products were celebrated in a ceremony marked by an announcement of the competition,s gold ... the category of general hospital devices and therapeutic products. , ... Gainesville, FL (Vocus) June 29, 2010 -- Earlier this year, ...
... ... Web site for parents, has launched KidsDoc Symptom Checker, a new online tool to help ... , ... 29, 2010 -- What should you do if your child develops a fever, cough, vomiting, ...
... insurance, low-income women had lower rates of mammography screening ... likelihood of screening. "Health insurance is a ... a sufficient condition," said Nasar Ahmed, Ph.D., chair of ... Public Health and Social Work at Florida International University. ...
Cached Medicine News:Health News:Pay-for-performance for hospitals 2Health News:Interventions to promote repeat breast cancer screening with mammography 2Health News:Intensively lowering glucose: Possible benefits must be weighed against risks 2Health News:Intensively lowering glucose: Possible benefits must be weighed against risks 3Health News:Xhale Innovation's HyGreen Hand Hygiene System Brings Home the Gold 2Health News:AAP Offers New Online Pediatric Symptom Checker on HealthyChildren.org 2Health News:Counseling increased mammography use among low-income women with health insurance 2
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... For the qualitative differential ... (P.f) antigen and an antigen ... four species of malaria:plasmodium falciparum ... ovale (P.o) and Plasmodium malariae ...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: